BackToBasic: Infliximab in Chronic Low Back Pain and Modic Changes

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Low-Back Pain (LBP) is the leading cause of disability worldwide. Even though LBP relates to different underlying pathologies, there are a substantial number of patients with chronic complaints that have vertebral bone marrow lesions visualized as Modic changes (MC) on magnetic resonance imaging (MRI). Despite the clinical evidence that MC is painful, the etiology is unknown and there is currently no established treatment. It has been suggested that MCs are secondary to a biomechanically induced degradation with a subsequent autoimmune response, supported by evidence showing that Tumor necrosis factor (TNF)-α plays a critical role in intervertebral disc degeneration and MCs. Clinical trials suppressing inflammation with TNF-alfa blockers in patients with acute low back pain and sciatica provide evidence to support the initiation of a clinical trial assessing the effect of TNF-alfa blockers in patients with chronic low-back pain and MCs. Since TNF-alfa blockers is an established treatment for immune-mediated disorders like spondyloarthritis by reducing pain as well as bone marrow lesions, the researchers aim to assess whether this treatment is effective for chronic LBP with MCs. In addition refine diagnostic assessment and explore potential biomarkers, which will provide an increased understanding of underlying factors causing LBP, and ultimately result in better management and treatment for one of the most costly and challenging patient populations.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Collaborators: Clinical Trial Unit (CTU), Oslo University Hospital; Diakonhjemmet Hospital; Haukeland University Hospital; Ostfold Hospital Trust; Østfold Hospital Trust; St. Olavs Hospital; University Hospital of North Norway; Vestre Viken Hospital Trust
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Age between 18 and 65 years

• LBP of > 50% of days for > 6 months duration in the area below the 12th rib and above the gluteal folds with:

Numerical Rating Scale (NRS) pain intensity score of at least 5 (mean of three NRS scales; current LBP, the worst LBP within the last 2 weeks, and usual/mean LBP within the last 2 weeks) and/or ODI-score of at least 25

• Modic change of craniocaudal size >= 10% of vertebral height and of primary or secondary type 1 in the vertebral body at a level of the lumbar spine (superior or inferior endplate, Th12-S1).

Exclusion criteria:

• Fever or ongoing infection

• Allergy or hypersensitivity against any products of the medication

• Previous infliximab treatment

• Any serious adverse events with other immunosuppressive treatment (including cytostatics, antibodies, drugs acting on immunophilins, Interferons, mycophenolate and any other DMARDs)

• Any specific diagnosis that may explain patient's low back symptoms (e.g. tumor, fracture, spondyloarthritis, infection, spinal stenosis).

• Former low back surgery (L1 - S1) for other reasons than disc herniation or decompression (e.g fusion, disc prosthesis).

• Former surgery for disc herniation or decompression within the last 12 months

• Any known rheumatic disease

• Current pregnancy or lactation

• For women of childbearing potential (WOCBP); inadequate birth control, pregnancy, and/or breastfeeding. WOCBP is defined as those who are fertile (with uterus, fallopian tubes and at least one intact functional ovary), following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Documentation of surgical procedure or physical examination is required for subjects who have had such an operation. Adequate contraception must be used by WOCBP during the entire intervention period and 6 months after the last administration of study drug, and includes oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or system, vasectomized partner or sexual abstinence.

• Ongoing systemic glucocorticoid or other immunosuppressive treatments (see list above)

• Regular use of opioids with the exception of codeine and tramadol

• Other immunosuppressive treatment last year (see list above)

• Active or latent (known or suspected) tuberculosis (all participants will be screened for latent tuberculosis)

• Previous infection with Hepatitis B virus (HBV) (all participants will be screened for HBV-carrier state)

• Live vaccination within the last 4 weeks or planned live vaccination during treatment period

• Planned surgical procedure

• Increased transaminases (ASAT/ALAT)

• Ongoing or previous malignant disease at any time (i.e. skin cancer, cervical cancer etc.)

• Known increased risk of malignant disease

• Diabetes

• Immunodeficiency (I.e primary immunodeficiency diseases, human immunodeficiency virus/acquired immunodeficiency syndrome, splenectomy)

• Heart failure (NYHA class III - IV)

• Previous or ongoing psoriasis

• Ulcerative colitis or Crohns disease

• Existing or recent demyelination diseases (I.e. MS or Guillain-Barres)

• Abnormal hemoglobin or abnormal platelet, leucocyte or neutrophil count

• Not able to understand written and spoken Norwegian

• Not able to complete treatment or follow-ups in the study (i.e. severe psychiatric disease, drug abuse or plans of moving address)

• Contraindications for MRI (ie. pacemaker, metal implants, claustrophobia)

• Abnormal creatinine level